COVID-19 Therapeutics Allocations for Feb 28 – Mar 6, 2022
From: HHS – Coordination Operations and Response Element (H-CORE), Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services
Subject: COVID-19 therapeutics allocations for Feb 28 – Mar 6, 2022
Importance: High
Dear Stakeholder,
Allocation amounts for COVID-19 therapeutics to states, territories, and federal entities have been determined for the period of Feb 28 – Mar 6, 2022, and are below. Evusheld, Bebtelovimab and Sotrovimab are included in today’s allocations.
On Feb 24, FDA announced a modification to the Emergency Use Authorization for Evusheld (AstraZeneca). The modification involves a change to the dosing regimen. Evusheld now should be administered as an initial dose of 600 mg. Individuals who already received the previously authorized initial 300 mg dose should receive a second Evusheld dose as soon as possible. Recommendations will be made in the near future when more data are available to determine the appropriate timing of redosing (e.g., a repeat dose with 150 mg of tixagevimab and 150 mg of cilgavimab at 3 months or 6 months after the initial dose).
HHS is committed to the health and wellbeing of all Americans, and that is why we have purchased as much Evusheld as the manufacturer can supply. We are making product available to states and territories without delay. Current utilization data available to us (as reported by state and territorial health departments and administration sites) notes the utilization rate of Evusheld is approximately 20% nationally with orders of Evusheld also being low. We are focused on outreach efforts to help increase utilization across jurisdictions and make Evusheld more available to providers for use among eligible patients as another tool for protection against COVID-19. To support product access, we maintain a public dashboard of jurisdiction-by-jurisdiction allocations of Evusheld as well as an online locator.
Distribution Determinations for Feb 28 – Mar 6, 2022
Units = doses
The allocation dashboard can also be found on ASPR. HHS.gov.
|
Jurisdiction |
Evusheld |
Bebtelovimab |
Sotrovimab |
Total |
|
Alabama |
744 |
845 |
762 |
2351 |
|
Alaska |
120 |
185 |
168 |
473 |
|
American Samoa |
0 |
0 |
0 |
0 |
|
Arizona |
1032 |
1480 |
1326 |
3838 |
|
Arkansas |
456 |
715 |
642 |
1813 |
|
BOP |
0 |
0 |
0 |
0 |
|
California |
5904 |
6090 |
5466 |
17460 |
|
Colorado |
840 |
840 |
750 |
2430 |
|
Connecticut |
552 |
355 |
318 |
1225 |
|
Delaware |
144 |
120 |
120 |
384 |
|
Dept of Defense |
0 |
390 |
408 |
798 |
|
Dept of State |
0 |
0 |
0 |
0 |
|
District of Columbia |
120 |
100 |
120 |
340 |
|
Federated States of Micronesia |
0 |
0 |
0 |
0 |
|
Florida |
3240 |
4050 |
3636 |
10926 |
|
Georgia |
1536 |
1385 |
1242 |
4163 |
|
Guam |
0 |
0 |
0 |
0 |
|
Hawaii |
216 |
195 |
174 |
585 |
|
HRSA |
0 |
0 |
0 |
0 |
|
ICE |
0 |
0 |
0 |
0 |
|
Idaho |
240 |
620 |
558 |
1418 |
|
Illinois |
1944 |
1345 |
1206 |
4495 |
|
Indian Health Svc |
408 |
390 |
408 |
1206 |
|
Indiana |
984 |
840 |
756 |
2580 |
|
Iowa |
480 |
405 |
366 |
1251 |
|
Kansas |
432 |
420 |
378 |
1230 |
|
Kentucky |
672 |
1625 |
1458 |
3755 |
|
Louisiana |
696 |
675 |
606 |
1977 |
|
Maine |
216 |
920 |
828 |
1964 |
|
Marshall Islands |
0 |
0 |
0 |
0 |
|
Maryland |
912 |
455 |
408 |
1775 |
|
Massachusetts |
1080 |
785 |
708 |
2573 |
|
Michigan |
1512 |
1310 |
1176 |
3998 |
|
Minnesota |
840 |
760 |
684 |
2284 |
|
Mississippi |
456 |
380 |
342 |
1178 |
|
Missouri |
912 |
910 |
816 |
2638 |
|
Montana |
168 |
350 |
312 |
830 |
|
Nebraska |
288 |
210 |
186 |
684 |
|
Nevada |
432 |
345 |
306 |
1083 |
|
New Hampshire |
216 |
270 |
240 |
726 |
|
New Jersey |
1368 |
935 |
840 |
3143 |
|
New Mexico |
312 |
355 |
318 |
985 |
|
New York |
3048 |
1880 |
1686 |
6614 |
|
NIH |
24 |
20 |
24 |
68 |
|
North Carolina |
1536 |
2090 |
1878 |
5504 |
|
North Dakota |
120 |
140 |
126 |
386 |
|
Northern Mariana Islands |
0 |
0 |
0 |
0 |
|
Ohio |
1776 |
1265 |
1134 |
4175 |
|
Oklahoma |
576 |
715 |
642 |
1933 |
|
Oregon |
624 |
655 |
588 |
1867 |
|
Palau |
0 |
0 |
0 |
0 |
|
Pennsylvania |
1992 |
1650 |
1482 |
5124 |
|
Puerto Rico |
528 |
155 |
144 |
827 |
|
Rhode Island |
168 |
115 |
120 |
403 |
|
South Carolina |
768 |
965 |
870 |
2603 |
|
South Dakota |
120 |
210 |
186 |
516 |
|
Tennessee |
1008 |
1715 |
1536 |
4259 |
|
Texas |
4032 |
4795 |
4308 |
13135 |
|
U.S. Virgin Islands |
24 |
100 |
120 |
244 |
|
Utah |
408 |
480 |
432 |
1320 |
|
Vermont |
96 |
120 |
120 |
336 |
|
Veterans Health |
0 |
390 |
408 |
798 |
|
Virginia |
1296 |
1325 |
1188 |
3809 |
|
Washington |
1104 |
695 |
624 |
2423 |
|
West Virginia |
288 |
605 |
546 |
1439 |
|
Wisconsin |
888 |
750 |
672 |
2310 |
|
Wyoming |
96 |
100 |
120 |
316 |
|
Grand total |
49,992 |
51,990 |
46,986 |
148,968 |
For questions regarding COVID-19 therapeutics for this cycle, please contact COVID-19Therapeutics@hhs.gov.
Thank you,
HHS – Coordination Operations and Response Element (H-CORE)
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services
